PMCB · XBRL financial data

PharmaCyte Biotech financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PMCB's year ends in late April)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY26Jul 31, 2025	Q2 FY26Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY27Jul 31, 2026
Revenue	0	0	0*	0	0	0	0*	0	0	0	0*	0
Research and development	82	127	94*	96	97	118	127*	95	141	93	62*	60
General and administrative	273	252	238*	135	118	241	3,445*	753	1,235	2,025	900*	947
Total operating expenses	1,410	1,869	3,166*	1,269	1,106	960	1,042*	848	1,376	2,118	2,511*	1,007
Operating income (loss)	(1,410)	(1,869)	(3,166)*	(1,269)	(1,106)	(960)	(1,042)*	(848)	(1,376)	(2,118)	(2,511)*	(1,007)
Other income (expense)	(1)	(0)	194*	(0)	(1)	(0)	(0)*	(0)	(0)	(1)	(0)*	(0)
Income tax expense (benefit)	—	—	year only	—	—	—	year only	0	—	—	year only	0
Net income (loss)	2,790	(620)	1,347*	23,421	(1,470)	(3,045)	11,750*	(8,360)	(7,418)	747	(4,393)*	(5,081)
Earnings per share, basic USD per share	(0.26)	(0.65)	—	1.90	(0.39)	(0.44)	—	(1.23)	(1.24)	(0.17)	—	(0.54)
Earnings per share, diluted USD per share	(0.26)	(0.65)	—	1.90	(0.39)	(0.44)	—	(1.23)	(1.24)	(0.17)	—	(0.54)
Weighted average shares, basic thousands of shares	8,765	8,607	8,323*	7,866	7,637	6,960	6,839*	6,796	6,796	9,263	—	10,736
Weighted average shares, diluted thousands of shares	8,765	8,607	8,323*	7,866	7,637	6,960	6,839*	6,796	6,796	9,263	—	10,736

Fiscal quarters (PMCB's year ends in late April)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY26Jul 31, 2025	Q2 FY26Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY27Jul 31, 2026
Cash and cash equivalents	73,425	61,210	50,180	32,635	20,840	16,383	15,172	13,178	15,406	20,166	18,604	17,739
Marketable securities	—	—	0	—	—	373	366	262	201	372	254	99
Prepaid and other current assets	323	298	260	240	493	207	224	238	503	159	97	32
Total current assets	73,748	61,508	50,440	32,875	21,333	16,963	22,375	19,106	23,022	20,696	37,421	30,975
Total assets	78,878	71,359	59,904	70,194	55,098	43,829	55,168	45,110	55,976	55,874	46,753	36,712
Accounts payable	126	484	389	554	349	485	399	465	1,021	1,200	271	391
Accrued liabilities	1,018	774	735	684	707	709	2,515	596	521	446	523	346
Total current liabilities	5,240	7,539	7,421	7,473	4,776	1,194	2,914	1,061	1,577	1,678	826	769
Total liabilities	20,813	22,466	20,389	17,153	11,647	3,578	3,277	1,519	19,422	16,471	11,772	6,897
Accumulated deficit	(116,352)	(116,972)	(115,625)	(92,204)	(93,673)	(96,719)	(84,969)	(93,329)	(100,747)	(100,000)	(104,394)	(109,475)
Total stockholders' equity	36,768	31,375	27,648	47,708	43,451	40,250	51,891	43,592	35,235	38,113	33,295	27,509
Total liabilities and equity	78,878	71,359	59,904	70,194	55,098	43,829	55,168	45,110	55,976	55,874	46,753	36,712
Common shares outstanding (cover page) thousands of shares	8,616	8,465	7,709	7,679	6,968	6,864	6,796	6,796	10,134	10,736	10,736	10,736

Fiscal quarters (PMCB's year ends in late April)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY26Jul 31, 2025	Q2 FY26Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY27Jul 31, 2026
Net income (loss)	2,790	(620)	1,347*	23,421	(1,470)	(3,045)	11,750*	(8,360)	(7,418)	747	(4,393)*	(5,081)
Stock-based compensation	0*	0*	0*	223	119*	73*	64*	60	60*	772*	0*	—
Net cash from operating activities	(1,984)*	(177)*	(333)*	(373)	(1,055)*	(510)*	(1,040)*	(1,994)	(980)*	(787)*	(1,393)*	(781)
Net cash from investing activities	0*	(5,000)*	0*	(7,000)	0*	0*	0*	0	(3,000)*	5,000*	0*	—
Share repurchases	165	405	1,175*	742	1,404*	225*	172*	0	0*	402*	0*	—
Net cash from financing activities	749*	(7,039)*	(10,697)*	(10,172)	(10,740)*	(3,945)*	(172)*	0	6,208*	544*	(170)*	(83)
Net change in cash	(1,237)*	(12,215)*	(11,030)*	(17,545)	(11,795)*	(4,457)*	(1,211)*	(1,994)	2,228*	4,760*	(1,562)*	(865)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
PharmaCyte Biotech	17,739	0	(781)	10.7M	22.8 quarters	Q1 FY27 10-QJul 31, 2026
Natural Alternatives International	7,388	not reported	(1,066)*	22.1M	6.9 quarters	Q4 FY26 10-KJun 30, 2026
LFTD Partners	1,504	8,705	(555)*	14.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
AIM ImmunoTech	9,900	26	(4,590)*	30.4M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Adial Pharmaceuticals	28,712	not reported	(6,363)*	2.6M	4.5 quarters	Q2 FY26 10-Q/AJun 30, 2026
Biomerica	2,733	1,265	(802)	4.6M	3.4 quarters	Q1 FY27 10-QAug 31, 2026
Protagenic Therapeutics, Inc.\new	566	not reported	(944)	1.8M	0.6 quarters	Q1 FY26 10-QJun 30, 2026
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.